

**APC310Hu01 100µg**  
**Active Adenine Phosphoribosyltransferase (APRT)**  
**Organism Species: Homo sapiens (Human)**  
***Instruction manual***

FOR IN VITRO USE AND RESEARCH USE ONLY  
NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES

---

---

1th Edition (Apr, 2016)

## **[ PROPERTIES ]**

**Source:** Prokaryotic expression.

**Host:** *E. coli*

**Residues:** Met1~Glu180

**Tags:** N-terminal His-tag

**Purity:** >98%

**Buffer Formulation:** 20mM Tris, 150mM NaCl, pH8.0, containing 0.05% sarcosyl and 5% trehalose.

**Applications:** Cell culture; Activity Assays.

(May be suitable for use in other assays to be determined by the end user.)

**Predicted isoelectric point:** 6.8

**Predicted Molecular Mass:** 23.3kDa

**Accurate Molecular Mass:** 23kDa as determined by SDS-PAGE reducing conditions.

## **[ USAGE ]**

Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

## **[ STORAGE AND STABILITY ]**

**Storage:** Avoid repeated freeze/thaw cycles.

Store at 2-8°C for one month.

Aliquot and store at -80°C for 12 months.

**Stability Test:** The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

## **[ SEQUENCE ]**

```
MADSELQLVE QRIRSFDFP TPGVVFRDIS PVLKDPASFR AAIGLLARHL  
KATHGGRIDY IAGLDSRGFL FGPSLAQELG LGCVLIRKRG KLPGPTLWAS  
YSLEYGKAEL EIQKDALEPG QRVVVVDDLL ATGGTMNAAC ELLGRLQAEV  
LECVSLVELT SLKGREKLAP VPFFSLLQYE
```

## **[ ACTIVITY ]**

Adenine Phosphoribosyltransferase (APRT) is an enzyme involved in the purine nucleotide salvage pathway. It functions as a catalyst in the reaction between adenine and phosphoribosyl pyrophosphate (PRPP) to form AMP. Besides, Vascular Cell Adhesion Molecule 1 (VCAM1) has been identified as an interactor of APRT, thus a binding ELISA assay was conducted to detect the interaction of recombinant human APRT and recombinant human VCAM1. Briefly, APRT were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100uL were then transferred to VCAM1-coated microtiter wells and incubated for 2h at 37°C. Wells were washed with PBST and incubated for 1h with anti-APRT pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37°C. Finally, add 50µL stop solution to the wells and read at 450nm immediately. The binding activity of APRT and VCAM1 was shown in Figure 1, and this effect was in a dose dependent manner.




Figure 1. The binding activity of APRT with VCAM1.

### [ IDENTIFICATION ]




Figure 2. Gene Sequencing (extract)





Figure 3. SDS-PAGE

Sample: Active recombinant APRT, Human



**Figure 4. Western Blot**

**Sample: Recombinant APRT, Human;**

**Antibody: Rabbit Anti-Human APRT Ab (PAC310Hu01)**